GLPG
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trading at a significant discount to both book value and defensive fair value.
- P/B of 0.50
- P/E of 5.16
- Price well below Graham Number ($84.09)
- Market ignores value metrics due to perceived risk
Current growth appears unsustainable or non-recurring given the forward P/E.
- Massive YoY revenue growth
- Negative Forward P/E
- Bearish technical trend
Long-term destruction of shareholder value despite short-term spikes.
- Recent 1Y return of +17.3%
- 5Y change of -63.1%
- Consistent volatility in quarterly EPS
Strong solvency but weak operational health trends.
- Zero debt
- High current ratio
- Piotroski F-Score of 2/9
Non-dividend paying growth/biotech entity.
- No dividend payments
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GLPG and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GLPG
Galapagos NV
Primary
|
-63.1% | -24.7% | +17.3% | -16.1% | -14.0% | -2.9% |
|
AUPH
Aurinia Pharmaceuticals Inc.
Peer
|
-22.4% | +77.0% | +81.0% | +62.7% | -10.7% | -2.1% |
|
ATRC
AtriCure, Inc.
Peer
|
-33.0% | -7.6% | -3.2% | +24.0% | -3.6% | +0.0% |
|
ADUS
Addus HomeCare Corporation
Peer
|
-6.0% | +1.0% | +11.6% | -8.1% | -10.1% | -1.8% |
|
ANAB
AnaptysBio, Inc.
Peer
|
+227.2% | +183.1% | +284.9% | +177.0% | +17.3% | +17.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GLPG
Galapagos NV
|
NEUTRAL | $1.92B | 5.16 | 10.4% | 28.8% | $28.56 | |
|
AUPH
Aurinia Pharmaceuticals Inc.
|
NEUTRAL | $1.92B | 26.42 | 20.7% | 29.3% | $14.53 | Compare |
|
ATRC
AtriCure, Inc.
|
NEUTRAL | $1.94B | - | -6.1% | -5.6% | $39.07 | Compare |
|
ADUS
Addus HomeCare Corporation
|
NEUTRAL | $1.88B | 19.42 | 9.3% | 6.7% | $101.35 | Compare |
|
ANAB
AnaptysBio, Inc.
|
BULLISH | $1.86B | - | -24.5% | -5.6% | $64.81 | Compare |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning GLPG from our newsroom.